Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02169349

Acronym

ANTiCIPe

Enrollment

100

Registered

2014-06-23

Start date

2014-06-30

Completion date

2016-09-30

Last updated

2016-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IIIb and IV Non Small Cell Lung Cancer

Brief summary

The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).

Interventions

OTHERlaboratory biomarker analysis

OTHERNext Generation Sequencing

GENETICDNA Analysis

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed written informed consent * Male or female aged \>= 18 years * Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed

Exclusion criteria

* Tissue and plasma samples can not be provided for mutation analysis * Unwilling or unable to provide informed consent * Any serious medical condition that would interfere with the subject's safety

Design outcomes

Primary

Measure	Time frame	Description
Mutation profiling of circulating tumor DNA from plasma samples.	1 year	To evaluate the sensitivity of NGS to detect the genetic alterations in plasma tumor DNA.

Secondary

Measure	Time frame	Description
Quantity of circulating tumor DNA in serially collected plasma specimens.	1 year	To evaluate the change of quantity of circulating tumor DNA during treatment.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026